National Drug Report 2022
- Share on Facebook
National Drug Report 2020
The drug phenomenon in the grand duchy of luxembourg: trends and developments (key issues).
This report presents an overview of the drug phenomenon in Luxembourg, covering drug policy, drug supply and demand, drug use patterns, health consequences and responses, as well as drug markets and crime. The statistical data and analysis presented in this report relate to 2019 or the most recent year for which data are available and were provided to the Luxembourg Focal Point of the EMCDDA (PFLDT) from routine monitoring by the RELIS network, unless stated otherwise.
Zitiervorschlag
Berndt, N., Seixas, R. & Origer, A. (2021). National Drug Report 2020: The drug phenomenon in the grand duchy of Luxembourg: trends and developments (key issues) (Rapports). Luxembourg. Ministère de la Santé; Point Focal Luxembourgeois de l’O.E.D.T.
Institution
Schlagwörter, verwandte projekte.
Select your language
Results hosted on duckduckgo.com
Main navigation
Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
Latest datasets
- Prevalence of drug use
- Drug-induced deaths
- Infectious diseases
- Problem drug use
- Treatment demand
- Seizures of drugs
- Price, purity and potency
- Drug use and prison
- Drug law offences
- Health and social response
- Drug checking
- Hospital emergencies data
- Syringe residues data
- Wastewater analysis
- Data catalogue
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
Countries
Reporting countries
- Netherlands
All countries
Explore the content of our work by topic.
Selected topics
- Alternatives to coercive sanctions
- Cannabis policy
- Darknet markets
- Drug consumption facilities
- Drug markets
- Drug-related deaths
- Drug-related infectious diseases
- Drugs and driving
- European Web Survey on Drugs
- Gender and drugs
- Harm reduction
- Hospital emergencies
- New psychoactive substances (NPS)
- Production of drugs
- Synthetic cannabinoids
- Synthetic cathinones
- Syringe analysis (ESCAPE)
- Treatment of drug use problems
- Wastewater-based epidemiology
- Young people
Topics (A-Z)
Best practice
The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses.
Best practice
In this section
- Evidence database
- European Prevention Curriculum (EUPC)
- Evaluations Instrument Bank (EIB)
- Standards and guidelines
- Xchange prevention registry
Quick links
- Health and social responses to drug problems: a European guide
- Healthy Nightlife Toolkit (HNT)
- List of EUPC trainers
- PLATO training platform (login required)
- Prevention toolkit
- Subscribe to the 'Best practice' newsletter
We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.
Activities
Selected areas
- Early Warning System on Drugs
- Key indicators
- Drug policy evaluation
- Hepatitis C elimination
- Multilingual glossary
Partners and cooperation
- Reitox network
- EMCDDA-IPA 8
- EU4Monitoring Drugs II (EU4MD II)
Publications
Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it.
All publications
- Publications database
- EMCDDA Document library
- Media library
Featured publications
- European Drug Report
- European Responses Guide
- EU Drug Markets
- Drug profiles
Recently published
- HIV among people who inject drugs: Data…
- Health risk communication strategies…
- EU Drug Market: Cannabis
- Prevention and control of infectious…
- Drug treatment, needle and syringe…
- EU Drug Market: Amphetamine
- Professionals working in reception…
- The Justice and Home Affairs (JHA)…
Explore our news section.
Recent news
- World AIDS Day: concerns over stimulant injecting and late HIV diagnoses in Europe
- Director presents European Drug Report 2023 at the European Parliament
- New guidance for drug checking services in health risk communication
- New analysis highlights greater diversity of cannabis products, rising potency, and security risks posed by Europe's largest illicit drug market
- Key interventions to prevent and control infections among people who inject drugs
- Dialogue with European Parliament on preparations for new agency mandate
More news
- Search news
- Subscribe newsletter for recent news
- Subscribe to news releases
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the leading authority on illicit drugs in the European Union.
About the EMCDDA
- Organisation
- Job vacancies
- Procurement
- EMCDDA Director
- Management Board
- Scientific Committee
- Data protection
- Public access to documents
- Sustainability at the EMCDDA
Luxembourg, Country Drug Report 2019
Introduction.
This report presents the top-level overview of the drug phenomenon in Luxembourg, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise
Download as PDF
- English (en)
Table of contents
- At a glance
- National drug strategy and coordination
- Public expenditure
- Drug laws and drug law offences
- Drug use and responses in prison
- Quality assurance
- Drug-related research
- Key drug statistics for Luxembourg
- EU Dashboard
- drug situation
Open calls for expression of interest
We are currently seeking candidates for the following calls for expression of interest:
- Membership of the Scientific Committee of the European Union Drugs Agency (EUDA)
- Inclusion on a list of experts to be used by the EUDA Executive Director to extend the Scientific Committee for the risk assessment of NPS
2021 L'Etat du phénomène des drogues et des toxicomanies au Grand-Duché de Luxembourg / The state of the drugs problem in the Grand-Duchy of Luxembourg
- Partager sur Facebook
- Partager sur Twitter
2021 L'Etat du phénomène des drogues et des toxicomanies au Grand-Duché de Luxembourg / The state of the drugs problem in the Grand-Duchy of Luxembourg
Le rapport 2021 sur l’état du phénomène des drogues et des toxicomanies au Grand-Duché de Luxembourg (RELIS) vise à situer le contexte dans lequel s’inscrivent l’usage et le trafic illicites de drogues et les toxicomanies au niveau national en proposant une vue d’ensemble des évolutions historiques et des tendances actuellement observées en la matière.
Dans d'autres langues
The state of the drugs problem in the grand-duchy of luxembourg.
Dernière modification le 08.08.2022
- Link to Health Research Board r s s feed, opens in new window
- [email protected]
HRB National Drugs Library
Home > European drug report 2023: trends and developments.
European Monitoring Centre for Drugs and Drug Addiction. (2023) European drug report 2023: trends and developments. Luxembourg: Publications Office of the European Union.
External website: https://www.emcdda.europa.eu/publications/european...
This report is based on information provided to the EMCDDA by the EU Member States, the candidate country Türkiye, and Norway, in an annual reporting process.
The purpose of the current report is to provide an overview and summary of the European drug situation up to the end of 2022. All grouping, aggregates and labels therefore reflect the situation based on the available data in 2022 in respect to the composition of the European Union and the countries participating in EMCDDA reporting exercises. However, not all data will cover the full period. Due to the time needed to compile and submit data, many of the annual national data sets included here are from the reference year January to December 2021. Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Although considerable improvements can be noted, both nationally and in respect to what is possible to achieve in a European level analysis, the methodological difficulties in this area must be acknowledged. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Caveats relating to the data are to be found in the online Statistical Bulletin , which contains detailed information on methodology, qualifications on analysis and comments on the limitations in the information set available. Information is also available there on the methods and data used for European level estimates, where interpolation may be used.
Repository Staff Only: item control page
Share this Page
We’d welcome your feedback.
Please participate in a very brief survey so we can improve your experience of using this website.
--> No Thanks . Don't take survey --> Take Survey . Survey opens in new tab -->